nodes	percent_of_prediction	percent_of_DWPC	metapath
Methadone—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0198	0.025	CbGbCtD
Methadone—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0187	0.0235	CbGbCtD
Methadone—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0187	0.0235	CbGbCtD
Methadone—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0177	0.0223	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0177	0.0223	CbGbCtD
Methadone—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.0169	0.0212	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.0153	0.0192	CbGbCtD
Methadone—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.0153	0.0192	CbGbCtD
Methadone—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0149	0.0187	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0149	0.0187	CbGbCtD
Methadone—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0147	0.0185	CbGbCtD
Methadone—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.0141	0.0178	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.0134	0.0169	CbGbCtD
Methadone—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.0134	0.0169	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.0134	0.0169	CbGbCtD
Methadone—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.0134	0.0169	CbGbCtD
Methadone—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0133	0.0167	CbGbCtD
Methadone—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0133	0.0167	CbGbCtD
Methadone—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.0128	0.0161	CbGbCtD
Methadone—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0128	0.0161	CbGbCtD
Methadone—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0128	0.0161	CbGbCtD
Methadone—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0126	0.0159	CbGbCtD
Methadone—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0119	0.0149	CbGbCtD
Methadone—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0116	0.0146	CbGbCtD
Methadone—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0115	0.0144	CbGbCtD
Methadone—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0111	0.014	CbGbCtD
Methadone—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0109	0.0138	CbGbCtD
Methadone—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0109	0.0138	CbGbCtD
Methadone—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0107	0.0135	CbGbCtD
Methadone—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0107	0.0135	CbGbCtD
Methadone—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0105	0.0132	CbGbCtD
Methadone—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0101	0.0127	CbGbCtD
Methadone—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0101	0.0127	CbGbCtD
Methadone—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0099	0.0124	CbGbCtD
Methadone—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.00986	0.0124	CbGbCtD
Methadone—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.00986	0.0124	CbGbCtD
Methadone—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.00969	0.0122	CbGbCtD
Methadone—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.00969	0.0122	CbGbCtD
Methadone—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.00959	0.0121	CbGbCtD
Methadone—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00957	0.012	CbGbCtD
Methadone—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.00929	0.0117	CbGbCtD
Methadone—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.00926	0.0116	CbGbCtD
Methadone—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.00902	0.0113	CbGbCtD
Methadone—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.00902	0.0113	CbGbCtD
Methadone—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.00899	0.0113	CbGbCtD
Methadone—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.00892	0.0112	CbGbCtD
Methadone—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.00892	0.0112	CbGbCtD
Methadone—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00865	0.0109	CbGbCtD
Methadone—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.00829	0.0104	CbGbCtD
Methadone—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.00815	0.0103	CbGbCtD
Methadone—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.00815	0.0103	CbGbCtD
Methadone—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.00813	0.0102	CbGbCtD
Methadone—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.00813	0.0102	CbGbCtD
Methadone—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.00779	0.0098	CbGbCtD
Methadone—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0077	0.00968	CbGbCtD
Methadone—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0075	0.00943	CbGbCtD
Methadone—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00747	0.0094	CbGbCtD
Methadone—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00747	0.00939	CbGbCtD
Methadone—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00725	0.00912	CbGbCtD
Methadone—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00704	0.00885	CbGbCtD
Methadone—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00683	0.00859	CbGbCtD
Methadone—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00676	0.0085	CbGbCtD
Methadone—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00676	0.0085	CbGbCtD
Methadone—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00656	0.00825	CbGbCtD
Methadone—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00656	0.00825	CbGbCtD
Methadone—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00648	0.00815	CbGbCtD
Methadone—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00629	0.00791	CbGbCtD
Methadone—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00618	0.00777	CbGbCtD
Methadone—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00618	0.00777	CbGbCtD
Methadone—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0061	0.00767	CbGbCtD
Methadone—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00573	0.00721	CbGbCtD
Methadone—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00573	0.00721	CbGbCtD
Methadone—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00518	0.00652	CbGbCtD
Methadone—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00518	0.00652	CbGbCtD
Methadone—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00486	0.00612	CbGbCtD
Methadone—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00448	0.00563	CbGbCtD
Methadone—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00434	0.00546	CbGbCtD
Methadone—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00393	0.00494	CbGbCtD
Methadone—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00393	0.00494	CbGbCtD
Methadone—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00377	0.00474	CbGbCtD
Methadone—CYP19A1—semen—acquired immunodeficiency syndrome	0.00358	0.0774	CbGeAlD
Methadone—HTR3A—nerve—acquired immunodeficiency syndrome	0.00224	0.0484	CbGeAlD
Methadone—OPRM1—nerve—acquired immunodeficiency syndrome	0.00205	0.0444	CbGeAlD
Methadone—CHRNA10—lymphoid tissue—acquired immunodeficiency syndrome	0.00142	0.0308	CbGeAlD
Methadone—CHRNA10—blood—acquired immunodeficiency syndrome	0.00134	0.029	CbGeAlD
Methadone—CHRNA10—vagina—acquired immunodeficiency syndrome	0.00124	0.0269	CbGeAlD
Methadone—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00107	0.0231	CbGeAlD
Methadone—CYP2C18—digestive system—acquired immunodeficiency syndrome	0.000968	0.0209	CbGeAlD
Methadone—GRIN3A—nervous system—acquired immunodeficiency syndrome	0.000961	0.0208	CbGeAlD
Methadone—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.000934	0.0202	CbGeAlD
Methadone—GRIN3A—central nervous system—acquired immunodeficiency syndrome	0.000925	0.02	CbGeAlD
Methadone—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000874	0.0189	CbGeAlD
Methadone—CYP2C18—vagina—acquired immunodeficiency syndrome	0.000855	0.0185	CbGeAlD
Methadone—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000843	0.0182	CbGeAlD
Methadone—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.000838	0.0181	CbGeAlD
Methadone—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000829	0.0179	CbGeAlD
Methadone—CHRNA10—lymph node—acquired immunodeficiency syndrome	0.000803	0.0174	CbGeAlD
Methadone—GRIN3A—brain—acquired immunodeficiency syndrome	0.000734	0.0159	CbGeAlD
Methadone—OPRD1—nervous system—acquired immunodeficiency syndrome	0.000677	0.0146	CbGeAlD
Methadone—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.000652	0.0141	CbGeAlD
Methadone—HTR3A—digestive system—acquired immunodeficiency syndrome	0.000651	0.0141	CbGeAlD
Methadone—OPRK1—nervous system—acquired immunodeficiency syndrome	0.000649	0.014	CbGeAlD
Methadone—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000632	0.0137	CbGeAlD
Methadone—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.000625	0.0135	CbGeAlD
Methadone—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000622	0.0135	CbGeAlD
Methadone—HTR3A—blood—acquired immunodeficiency syndrome	0.00062	0.0134	CbGeAlD
Methadone—OPRM1—blood—acquired immunodeficiency syndrome	0.000569	0.0123	CbGeAlD
Methadone—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000548	0.0119	CbGeAlD
Methadone—HTR3A—lung—acquired immunodeficiency syndrome	0.000544	0.0118	CbGeAlD
Methadone—OPRD1—brain—acquired immunodeficiency syndrome	0.000517	0.0112	CbGeAlD
Methadone—HTR3A—nervous system—acquired immunodeficiency syndrome	0.000504	0.0109	CbGeAlD
Methadone—OPRK1—brain—acquired immunodeficiency syndrome	0.000496	0.0107	CbGeAlD
Methadone—HTR3A—central nervous system—acquired immunodeficiency syndrome	0.000485	0.0105	CbGeAlD
Methadone—CYP19A1—blood—acquired immunodeficiency syndrome	0.000478	0.0103	CbGeAlD
Methadone—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000462	0.00999	CbGeAlD
Methadone—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000448	0.00968	CbGeAlD
Methadone—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000444	0.00961	CbGeAlD
Methadone—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000411	0.0089	CbGeAlD
Methadone—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000403	0.00871	CbGeAlD
Methadone—CYP2C19—blood—acquired immunodeficiency syndrome	0.000392	0.00848	CbGeAlD
Methadone—CYP19A1—nervous system—acquired immunodeficiency syndrome	0.000388	0.00839	CbGeAlD
Methadone—HTR3A—brain—acquired immunodeficiency syndrome	0.000385	0.00833	CbGeAlD
Methadone—CYP19A1—central nervous system—acquired immunodeficiency syndrome	0.000373	0.00808	CbGeAlD
Methadone—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000363	0.00786	CbGeAlD
Methadone—OPRM1—brain—acquired immunodeficiency syndrome	0.000353	0.00763	CbGeAlD
Methadone—CYP2C8—blood—acquired immunodeficiency syndrome	0.000342	0.0074	CbGeAlD
Methadone—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000336	0.00727	CbGeAlD
Methadone—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	0.000326	0.00705	CbGeAlD
Methadone—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000324	0.00701	CbGeAlD
Methadone—CYP2B6—digestive system—acquired immunodeficiency syndrome	0.000322	0.00697	CbGeAlD
Methadone—CYP1A2—blood—acquired immunodeficiency syndrome	0.00032	0.00692	CbGeAlD
Methadone—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000319	0.0069	CbGeAlD
Methadone—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000317	0.00686	CbGeAlD
Methadone—CYP3A5—blood—acquired immunodeficiency syndrome	0.000309	0.00668	CbGeAlD
Methadone—CYP2B6—blood—acquired immunodeficiency syndrome	0.000307	0.00664	CbGeAlD
Methadone—CYP2C9—blood—acquired immunodeficiency syndrome	0.000304	0.00657	CbGeAlD
Methadone—CYP19A1—brain—acquired immunodeficiency syndrome	0.000296	0.00641	CbGeAlD
Methadone—CYP19A1—lymph node—acquired immunodeficiency syndrome	0.000286	0.0062	CbGeAlD
Methadone—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000286	0.00619	CbGeAlD
Methadone—CYP2B6—vagina—acquired immunodeficiency syndrome	0.000284	0.00615	CbGeAlD
Methadone—CYP1A2—lung—acquired immunodeficiency syndrome	0.000281	0.00607	CbGeAlD
Methadone—CYP3A5—lung—acquired immunodeficiency syndrome	0.000271	0.00585	CbGeAlD
Methadone—CYP2B6—lung—acquired immunodeficiency syndrome	0.000269	0.00582	CbGeAlD
Methadone—CYP2B6—nervous system—acquired immunodeficiency syndrome	0.000249	0.00539	CbGeAlD
Methadone—ABCB1—retina—acquired immunodeficiency syndrome	0.000245	0.0053	CbGeAlD
Methadone—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000243	0.00526	CbGeAlD
Methadone—CYP2B6—central nervous system—acquired immunodeficiency syndrome	0.00024	0.00519	CbGeAlD
Methadone—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000239	0.00518	CbGeAlD
Methadone—CYP3A4—blood—acquired immunodeficiency syndrome	0.000232	0.00501	CbGeAlD
Methadone—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000231	0.00155	CcSEcCtD
Methadone—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.00023	0.00154	CcSEcCtD
Methadone—Anorexia—Indinavir—acquired immunodeficiency syndrome	0.000229	0.00154	CcSEcCtD
Methadone—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.000229	0.00153	CcSEcCtD
Methadone—CYP2D6—blood—acquired immunodeficiency syndrome	0.000228	0.00493	CbGeAlD
Methadone—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000228	0.00153	CcSEcCtD
Methadone—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000227	0.00152	CcSEcCtD
Methadone—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.000226	0.00152	CcSEcCtD
Methadone—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.000226	0.00152	CcSEcCtD
Methadone—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.000226	0.00151	CcSEcCtD
Methadone—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000225	0.00151	CcSEcCtD
Methadone—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000224	0.0015	CcSEcCtD
Methadone—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000223	0.0015	CcSEcCtD
Methadone—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000222	0.00149	CcSEcCtD
Methadone—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000222	0.00149	CcSEcCtD
Methadone—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000222	0.00149	CcSEcCtD
Methadone—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000222	0.00149	CcSEcCtD
Methadone—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000221	0.00148	CcSEcCtD
Methadone—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000221	0.00148	CcSEcCtD
Methadone—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000221	0.00148	CcSEcCtD
Methadone—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000221	0.00148	CcSEcCtD
Methadone—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000221	0.00148	CcSEcCtD
Methadone—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00022	0.00147	CcSEcCtD
Methadone—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.00022	0.00147	CcSEcCtD
Methadone—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000219	0.00147	CcSEcCtD
Methadone—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000219	0.00147	CcSEcCtD
Methadone—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000218	0.00146	CcSEcCtD
Methadone—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000218	0.00146	CcSEcCtD
Methadone—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000218	0.00146	CcSEcCtD
Methadone—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000218	0.00146	CcSEcCtD
Methadone—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000218	0.00146	CcSEcCtD
Methadone—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000217	0.00146	CcSEcCtD
Methadone—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000217	0.00146	CcSEcCtD
Methadone—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000217	0.00145	CcSEcCtD
Methadone—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000217	0.00145	CcSEcCtD
Methadone—Rash—Didanosine—acquired immunodeficiency syndrome	0.000216	0.00145	CcSEcCtD
Methadone—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000216	0.00145	CcSEcCtD
Methadone—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000216	0.00145	CcSEcCtD
Methadone—Headache—Didanosine—acquired immunodeficiency syndrome	0.000215	0.00144	CcSEcCtD
Methadone—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000214	0.00143	CcSEcCtD
Methadone—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000214	0.00143	CcSEcCtD
Methadone—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000214	0.00143	CcSEcCtD
Methadone—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000213	0.00143	CcSEcCtD
Methadone—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000213	0.00143	CcSEcCtD
Methadone—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000213	0.00143	CcSEcCtD
Methadone—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000213	0.00143	CcSEcCtD
Methadone—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000213	0.00143	CcSEcCtD
Methadone—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000213	0.00142	CcSEcCtD
Methadone—CYP2C8—brain—acquired immunodeficiency syndrome	0.000212	0.00459	CbGeAlD
Methadone—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000212	0.00142	CcSEcCtD
Methadone—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000212	0.00142	CcSEcCtD
Methadone—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000211	0.00142	CcSEcCtD
Methadone—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000211	0.00141	CcSEcCtD
Methadone—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000211	0.00141	CcSEcCtD
Methadone—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00021	0.00141	CcSEcCtD
Methadone—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.00021	0.00141	CcSEcCtD
Methadone—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.00021	0.00141	CcSEcCtD
Methadone—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000209	0.0014	CcSEcCtD
Methadone—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000209	0.0014	CcSEcCtD
Methadone—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000208	0.0014	CcSEcCtD
Methadone—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000207	0.00139	CcSEcCtD
Methadone—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000207	0.00139	CcSEcCtD
Methadone—Pain—Indinavir—acquired immunodeficiency syndrome	0.000206	0.00138	CcSEcCtD
Methadone—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000206	0.00138	CcSEcCtD
Methadone—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000206	0.00138	CcSEcCtD
Methadone—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000205	0.00138	CcSEcCtD
Methadone—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000205	0.00138	CcSEcCtD
Methadone—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000205	0.00137	CcSEcCtD
Methadone—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000204	0.00137	CcSEcCtD
Methadone—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000204	0.00137	CcSEcCtD
Methadone—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000204	0.00137	CcSEcCtD
Methadone—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000204	0.00136	CcSEcCtD
Methadone—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000204	0.00136	CcSEcCtD
Methadone—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000203	0.00136	CcSEcCtD
Methadone—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000203	0.00136	CcSEcCtD
Methadone—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000203	0.00136	CcSEcCtD
Methadone—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000203	0.00136	CcSEcCtD
Methadone—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000202	0.00135	CcSEcCtD
Methadone—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000201	0.00135	CcSEcCtD
Methadone—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000201	0.00135	CcSEcCtD
Methadone—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000201	0.00134	CcSEcCtD
Methadone—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000199	0.00133	CcSEcCtD
Methadone—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000198	0.00133	CcSEcCtD
Methadone—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000198	0.00132	CcSEcCtD
Methadone—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000198	0.00132	CcSEcCtD
Methadone—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000197	0.00132	CcSEcCtD
Methadone—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000197	0.00132	CcSEcCtD
Methadone—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000197	0.00132	CcSEcCtD
Methadone—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000197	0.00132	CcSEcCtD
Methadone—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000197	0.00132	CcSEcCtD
Methadone—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000197	0.00132	CcSEcCtD
Methadone—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000196	0.00131	CcSEcCtD
Methadone—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000196	0.00131	CcSEcCtD
Methadone—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000196	0.00131	CcSEcCtD
Methadone—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000195	0.00131	CcSEcCtD
Methadone—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000194	0.0013	CcSEcCtD
Methadone—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000194	0.0013	CcSEcCtD
Methadone—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000194	0.0013	CcSEcCtD
Methadone—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000194	0.0013	CcSEcCtD
Methadone—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000194	0.0013	CcSEcCtD
Methadone—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000194	0.0013	CcSEcCtD
Methadone—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000194	0.0013	CcSEcCtD
Methadone—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000193	0.00129	CcSEcCtD
Methadone—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000193	0.00129	CcSEcCtD
Methadone—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000192	0.00129	CcSEcCtD
Methadone—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000192	0.00128	CcSEcCtD
Methadone—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000191	0.00128	CcSEcCtD
Methadone—CYP2B6—brain—acquired immunodeficiency syndrome	0.00019	0.00412	CbGeAlD
Methadone—Shock—Saquinavir—acquired immunodeficiency syndrome	0.00019	0.00128	CcSEcCtD
Methadone—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.00019	0.00127	CcSEcCtD
Methadone—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.00019	0.00127	CcSEcCtD
Methadone—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.00019	0.00127	CcSEcCtD
Methadone—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000189	0.00127	CcSEcCtD
Methadone—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000189	0.00127	CcSEcCtD
Methadone—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000189	0.00127	CcSEcCtD
Methadone—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000188	0.00126	CcSEcCtD
Methadone—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000188	0.00126	CcSEcCtD
Methadone—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000188	0.00407	CbGeAlD
Methadone—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000188	0.00126	CcSEcCtD
Methadone—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000188	0.00126	CcSEcCtD
Methadone—Rash—Stavudine—acquired immunodeficiency syndrome	0.000188	0.00126	CcSEcCtD
Methadone—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000187	0.00126	CcSEcCtD
Methadone—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000187	0.00125	CcSEcCtD
Methadone—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000187	0.00125	CcSEcCtD
Methadone—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000187	0.00125	CcSEcCtD
Methadone—Headache—Stavudine—acquired immunodeficiency syndrome	0.000186	0.00125	CcSEcCtD
Methadone—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000186	0.00125	CcSEcCtD
Methadone—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000186	0.00125	CcSEcCtD
Methadone—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000186	0.00125	CcSEcCtD
Methadone—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000186	0.00125	CcSEcCtD
Methadone—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000186	0.00124	CcSEcCtD
Methadone—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000186	0.00124	CcSEcCtD
Methadone—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000185	0.004	CbGeAlD
Methadone—Rash—Abacavir—acquired immunodeficiency syndrome	0.000185	0.00124	CcSEcCtD
Methadone—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000185	0.00124	CcSEcCtD
Methadone—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000185	0.00124	CcSEcCtD
Methadone—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000185	0.00124	CcSEcCtD
Methadone—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000184	0.00124	CcSEcCtD
Methadone—Headache—Abacavir—acquired immunodeficiency syndrome	0.000184	0.00123	CcSEcCtD
Methadone—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000183	0.00123	CcSEcCtD
Methadone—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000183	0.00123	CcSEcCtD
Methadone—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000182	0.00122	CcSEcCtD
Methadone—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000182	0.00122	CcSEcCtD
Methadone—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000181	0.00392	CbGeAlD
Methadone—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000181	0.00121	CcSEcCtD
Methadone—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000181	0.00121	CcSEcCtD
Methadone—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000181	0.00121	CcSEcCtD
Methadone—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.00018	0.0012	CcSEcCtD
Methadone—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.00018	0.0012	CcSEcCtD
Methadone—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000179	0.0012	CcSEcCtD
Methadone—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000179	0.0012	CcSEcCtD
Methadone—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000178	0.0012	CcSEcCtD
Methadone—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000178	0.00385	CbGeAlD
Methadone—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000178	0.00119	CcSEcCtD
Methadone—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000177	0.00119	CcSEcCtD
Methadone—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000177	0.00119	CcSEcCtD
Methadone—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000177	0.00119	CcSEcCtD
Methadone—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000177	0.00118	CcSEcCtD
Methadone—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000176	0.00118	CcSEcCtD
Methadone—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000175	0.00117	CcSEcCtD
Methadone—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000175	0.00117	CcSEcCtD
Methadone—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000174	0.00377	CbGeAlD
Methadone—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000174	0.00117	CcSEcCtD
Methadone—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000173	0.00116	CcSEcCtD
Methadone—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000173	0.00116	CcSEcCtD
Methadone—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000172	0.00116	CcSEcCtD
Methadone—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000172	0.00372	CbGeAlD
Methadone—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000172	0.00115	CcSEcCtD
Methadone—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000172	0.00115	CcSEcCtD
Methadone—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000172	0.00115	CcSEcCtD
Methadone—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000172	0.00115	CcSEcCtD
Methadone—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000172	0.00115	CcSEcCtD
Methadone—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000171	0.00115	CcSEcCtD
Methadone—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00017	0.00114	CcSEcCtD
Methadone—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000168	0.00113	CcSEcCtD
Methadone—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000167	0.00112	CcSEcCtD
Methadone—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000167	0.00112	CcSEcCtD
Methadone—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000166	0.00111	CcSEcCtD
Methadone—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000165	0.00111	CcSEcCtD
Methadone—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000165	0.00111	CcSEcCtD
Methadone—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000165	0.0011	CcSEcCtD
Methadone—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000164	0.0011	CcSEcCtD
Methadone—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000164	0.0011	CcSEcCtD
Methadone—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000164	0.0011	CcSEcCtD
Methadone—ABCB1—blood—acquired immunodeficiency syndrome	0.000164	0.00355	CbGeAlD
Methadone—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000163	0.00109	CcSEcCtD
Methadone—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000163	0.00109	CcSEcCtD
Methadone—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000163	0.00109	CcSEcCtD
Methadone—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000162	0.00109	CcSEcCtD
Methadone—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000161	0.00108	CcSEcCtD
Methadone—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.00016	0.00107	CcSEcCtD
Methadone—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.00016	0.00107	CcSEcCtD
Methadone—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.00016	0.00107	CcSEcCtD
Methadone—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000159	0.00107	CcSEcCtD
Methadone—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000159	0.00107	CcSEcCtD
Methadone—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000159	0.00106	CcSEcCtD
Methadone—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000159	0.00106	CcSEcCtD
Methadone—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000159	0.00343	CbGeAlD
Methadone—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000158	0.00106	CcSEcCtD
Methadone—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000158	0.00342	CbGeAlD
Methadone—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000158	0.00106	CcSEcCtD
Methadone—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000158	0.00106	CcSEcCtD
Methadone—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000156	0.00104	CcSEcCtD
Methadone—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000155	0.00104	CcSEcCtD
Methadone—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000154	0.00103	CcSEcCtD
Methadone—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000154	0.00103	CcSEcCtD
Methadone—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000154	0.00103	CcSEcCtD
Methadone—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000153	0.00102	CcSEcCtD
Methadone—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000153	0.00102	CcSEcCtD
Methadone—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000153	0.00102	CcSEcCtD
Methadone—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000152	0.00102	CcSEcCtD
Methadone—ABCB1—vagina—acquired immunodeficiency syndrome	0.000152	0.00329	CbGeAlD
Methadone—Rash—Indinavir—acquired immunodeficiency syndrome	0.000152	0.00102	CcSEcCtD
Methadone—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000151	0.00101	CcSEcCtD
Methadone—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000151	0.00101	CcSEcCtD
Methadone—Headache—Indinavir—acquired immunodeficiency syndrome	0.000151	0.00101	CcSEcCtD
Methadone—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00015	0.00101	CcSEcCtD
Methadone—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000149	0.000996	CcSEcCtD
Methadone—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000148	0.000992	CcSEcCtD
Methadone—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000147	0.000982	CcSEcCtD
Methadone—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000146	0.000977	CcSEcCtD
Methadone—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000146	0.000977	CcSEcCtD
Methadone—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000144	0.000968	CcSEcCtD
Methadone—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000144	0.000966	CcSEcCtD
Methadone—ABCB1—lung—acquired immunodeficiency syndrome	0.000144	0.00311	CbGeAlD
Methadone—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000144	0.000963	CcSEcCtD
Methadone—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000143	0.00096	CcSEcCtD
Methadone—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000143	0.000959	CcSEcCtD
Methadone—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000143	0.000957	CcSEcCtD
Methadone—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000143	0.000955	CcSEcCtD
Methadone—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000142	0.000953	CcSEcCtD
Methadone—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000142	0.000953	CcSEcCtD
Methadone—CYP2D6—brain—acquired immunodeficiency syndrome	0.000141	0.00306	CbGeAlD
Methadone—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000139	0.00093	CcSEcCtD
Methadone—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000138	0.000926	CcSEcCtD
Methadone—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000138	0.000921	CcSEcCtD
Methadone—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000137	0.000918	CcSEcCtD
Methadone—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000137	0.000917	CcSEcCtD
Methadone—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000137	0.000917	CcSEcCtD
Methadone—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000136	0.000912	CcSEcCtD
Methadone—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000136	0.000911	CcSEcCtD
Methadone—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000135	0.000904	CcSEcCtD
Methadone—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000133	0.00288	CbGeAlD
Methadone—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000133	0.00089	CcSEcCtD
Methadone—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000132	0.000887	CcSEcCtD
Methadone—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000132	0.000887	CcSEcCtD
Methadone—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000131	0.000875	CcSEcCtD
Methadone—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000129	0.000865	CcSEcCtD
Methadone—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000128	0.00277	CbGeAlD
Methadone—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000128	0.000857	CcSEcCtD
Methadone—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000128	0.000856	CcSEcCtD
Methadone—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000127	0.000849	CcSEcCtD
Methadone—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000127	0.000848	CcSEcCtD
Methadone—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000126	0.000846	CcSEcCtD
Methadone—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000126	0.000844	CcSEcCtD
Methadone—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000123	0.000824	CcSEcCtD
Methadone—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000122	0.000818	CcSEcCtD
Methadone—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000122	0.000817	CcSEcCtD
Methadone—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000122	0.000816	CcSEcCtD
Methadone—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000121	0.000812	CcSEcCtD
Methadone—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.0008	CcSEcCtD
Methadone—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000117	0.000786	CcSEcCtD
Methadone—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000116	0.00078	CcSEcCtD
Methadone—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000116	0.000779	CcSEcCtD
Methadone—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000116	0.000775	CcSEcCtD
Methadone—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.00077	CcSEcCtD
Methadone—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.000734	CcSEcCtD
Methadone—ABCB1—brain—acquired immunodeficiency syndrome	0.000102	0.0022	CbGeAlD
Methadone—ABCB1—lymph node—acquired immunodeficiency syndrome	9.83e-05	0.00213	CbGeAlD
Methadone—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	6.03e-05	0.00648	CbGpPWpGaD
Methadone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	5.92e-05	0.00637	CbGpPWpGaD
Methadone—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	5.91e-05	0.00635	CbGpPWpGaD
Methadone—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	5.85e-05	0.00629	CbGpPWpGaD
Methadone—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	5.85e-05	0.00629	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	5.69e-05	0.00611	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	5.54e-05	0.00595	CbGpPWpGaD
Methadone—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	5.46e-05	0.00586	CbGpPWpGaD
Methadone—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	5.4e-05	0.00581	CbGpPWpGaD
Methadone—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	5.25e-05	0.00564	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	5.14e-05	0.00553	CbGpPWpGaD
Methadone—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	5.13e-05	0.00551	CbGpPWpGaD
Methadone—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	5.13e-05	0.00551	CbGpPWpGaD
Methadone—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	5.1e-05	0.00548	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	5.01e-05	0.00538	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	4.99e-05	0.00536	CbGpPWpGaD
Methadone—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	4.94e-05	0.0053	CbGpPWpGaD
Methadone—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	4.94e-05	0.0053	CbGpPWpGaD
Methadone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.87e-05	0.00524	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.82e-05	0.00518	CbGpPWpGaD
Methadone—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	4.74e-05	0.00509	CbGpPWpGaD
Methadone—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	4.74e-05	0.00509	CbGpPWpGaD
Methadone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.62e-05	0.00496	CbGpPWpGaD
Methadone—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	4.61e-05	0.00496	CbGpPWpGaD
Methadone—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	4.6e-05	0.00495	CbGpPWpGaD
Methadone—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.58e-05	0.00492	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	4.51e-05	0.00485	CbGpPWpGaD
Methadone—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	4.45e-05	0.00478	CbGpPWpGaD
Methadone—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	4.34e-05	0.00466	CbGpPWpGaD
Methadone—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	4.34e-05	0.00466	CbGpPWpGaD
Methadone—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	4.33e-05	0.00465	CbGpPWpGaD
Methadone—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	4.33e-05	0.00465	CbGpPWpGaD
Methadone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.27e-05	0.00459	CbGpPWpGaD
Methadone—CYP19A1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.25e-05	0.00457	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.23e-05	0.00454	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	4.22e-05	0.00453	CbGpPWpGaD
Methadone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	4.17e-05	0.00449	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	4.1e-05	0.00441	CbGpPWpGaD
Methadone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.05e-05	0.00435	CbGpPWpGaD
Methadone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.02e-05	0.00432	CbGpPWpGaD
Methadone—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	4.01e-05	0.00431	CbGpPWpGaD
Methadone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.92e-05	0.00422	CbGpPWpGaD
Methadone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.92e-05	0.00422	CbGpPWpGaD
Methadone—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	3.9e-05	0.00419	CbGpPWpGaD
Methadone—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	3.89e-05	0.00418	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	3.81e-05	0.0041	CbGpPWpGaD
Methadone—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.75e-05	0.00404	CbGpPWpGaD
Methadone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.66e-05	0.00393	CbGpPWpGaD
Methadone—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	3.66e-05	0.00393	CbGpPWpGaD
Methadone—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	3.66e-05	0.00393	CbGpPWpGaD
Methadone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	3.61e-05	0.00388	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	3.57e-05	0.00384	CbGpPWpGaD
Methadone—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	3.52e-05	0.00378	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.51e-05	0.00378	CbGpPWpGaD
Methadone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.44e-05	0.0037	CbGpPWpGaD
Methadone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.44e-05	0.0037	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	3.42e-05	0.00368	CbGpPWpGaD
Methadone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	3.39e-05	0.00365	CbGpPWpGaD
Methadone—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	3.39e-05	0.00365	CbGpPWpGaD
Methadone—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	3.38e-05	0.00364	CbGpPWpGaD
Methadone—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	3.3e-05	0.00355	CbGpPWpGaD
Methadone—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.29e-05	0.00354	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.18e-05	0.00342	CbGpPWpGaD
Methadone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.14e-05	0.00337	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	3.11e-05	0.00334	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	3.11e-05	0.00334	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.09e-05	0.00332	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.08e-05	0.00331	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	3.03e-05	0.00325	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.99e-05	0.00321	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.99e-05	0.00321	CbGpPWpGaD
Methadone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.99e-05	0.00321	CbGpPWpGaD
Methadone—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	2.97e-05	0.00319	CbGpPWpGaD
Methadone—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	2.97e-05	0.00319	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	2.96e-05	0.00318	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.92e-05	0.00314	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—TAT—acquired immunodeficiency syndrome	2.91e-05	0.00313	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	2.91e-05	0.00313	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	2.91e-05	0.00313	CbGpPWpGaD
Methadone—HTR3A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	2.91e-05	0.00312	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.85e-05	0.00306	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.79e-05	0.003	CbGpPWpGaD
Methadone—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	2.78e-05	0.00299	CbGpPWpGaD
Methadone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.75e-05	0.00296	CbGpPWpGaD
Methadone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.69e-05	0.00289	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.64e-05	0.00284	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.62e-05	0.00282	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.62e-05	0.00282	CbGpPWpGaD
Methadone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.62e-05	0.00281	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	2.6e-05	0.0028	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.56e-05	0.00275	CbGpPWpGaD
Methadone—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	2.51e-05	0.00269	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.5e-05	0.00268	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—AGPS—acquired immunodeficiency syndrome	2.47e-05	0.00266	CbGpPWpGaD
Methadone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.36e-05	0.00253	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.36e-05	0.00253	CbGpPWpGaD
Methadone—HTR3A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.35e-05	0.00252	CbGpPWpGaD
Methadone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.33e-05	0.0025	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.32e-05	0.00249	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.31e-05	0.00248	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.27e-05	0.00244	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	2.25e-05	0.00242	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—TAT—acquired immunodeficiency syndrome	2.23e-05	0.00239	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.21e-05	0.00238	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.21e-05	0.00238	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.21e-05	0.00238	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.16e-05	0.00233	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.11e-05	0.00227	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.06e-05	0.00222	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.05e-05	0.0022	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	2e-05	0.00215	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.99e-05	0.00214	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.99e-05	0.00214	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.96e-05	0.0021	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—TAT—acquired immunodeficiency syndrome	1.93e-05	0.00208	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.89e-05	0.00204	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.88e-05	0.00202	CbGpPWpGaD
Methadone—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	1.83e-05	0.00197	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	1.83e-05	0.00197	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.8e-05	0.00194	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.8e-05	0.00193	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.8e-05	0.00193	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.72e-05	0.00185	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.72e-05	0.00185	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.69e-05	0.00182	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.69e-05	0.00182	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.68e-05	0.00181	CbGpPWpGaD
Methadone—HTR3A—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.66e-05	0.00179	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—AGPS—acquired immunodeficiency syndrome	1.64e-05	0.00177	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.63e-05	0.00175	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	1.63e-05	0.00175	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.61e-05	0.00173	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.58e-05	0.0017	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.57e-05	0.00169	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.56e-05	0.00168	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.53e-05	0.00165	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.53e-05	0.00165	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.52e-05	0.00163	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.51e-05	0.00163	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.51e-05	0.00163	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.48e-05	0.00159	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.48e-05	0.00159	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	1.46e-05	0.00157	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	1.46e-05	0.00157	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.43e-05	0.00154	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—TAT—acquired immunodeficiency syndrome	1.43e-05	0.00154	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	1.4e-05	0.0015	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.37e-05	0.00147	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.34e-05	0.00145	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.34e-05	0.00145	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.34e-05	0.00144	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.33e-05	0.00143	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.28e-05	0.00138	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.28e-05	0.00137	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.28e-05	0.00137	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.27e-05	0.00136	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.25e-05	0.00135	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.25e-05	0.00135	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.22e-05	0.00131	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	1.21e-05	0.0013	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.21e-05	0.0013	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	1.19e-05	0.00128	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	1.18e-05	0.00127	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.17e-05	0.00125	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.16e-05	0.00124	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.16e-05	0.00124	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.15e-05	0.00124	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.14e-05	0.00122	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.14e-05	0.00122	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.13e-05	0.00121	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.11e-05	0.00119	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	1.08e-05	0.00116	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.07e-05	0.00115	CbGpPWpGaD
Methadone—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.05e-05	0.00113	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.05e-05	0.00113	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	1.03e-05	0.00111	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.02e-05	0.0011	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.01e-05	0.00109	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.01e-05	0.00108	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	9.94e-06	0.00107	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	9.85e-06	0.00106	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.64e-06	0.00104	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.52e-06	0.00102	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.38e-06	0.00101	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.34e-06	0.001	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.22e-06	0.000991	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	9.19e-06	0.000988	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.06e-06	0.000974	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.06e-06	0.000974	CbGpPWpGaD
Methadone—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	8.97e-06	0.000964	CbGpPWpGaD
Methadone—CYP19A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	8.72e-06	0.000937	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.65e-06	0.000929	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.58e-06	0.000922	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.52e-06	0.000915	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	8.45e-06	0.000908	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.45e-06	0.000908	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	8.42e-06	0.000905	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	8.38e-06	0.000901	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.94e-06	0.000854	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.94e-06	0.000854	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.9e-06	0.000849	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.79e-06	0.000837	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	7.16e-06	0.00077	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.14e-06	0.000767	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.89e-06	0.000741	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.79e-06	0.00073	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.71e-06	0.000722	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.71e-06	0.000722	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.69e-06	0.000719	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	6.5e-06	0.000699	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.21e-06	0.000667	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.07e-06	0.000653	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.04e-06	0.00065	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.95e-06	0.00064	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.86e-06	0.00063	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	5.84e-06	0.000628	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	5.53e-06	0.000594	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.44e-06	0.000585	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.33e-06	0.000572	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.11e-06	0.000549	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—ALB—acquired immunodeficiency syndrome	5.07e-06	0.000545	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.03e-06	0.000541	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.96e-06	0.000533	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.74e-06	0.00051	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.6e-06	0.000495	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.5e-06	0.000484	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.23e-06	0.000455	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.93e-06	0.000422	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—ALB—acquired immunodeficiency syndrome	3.88e-06	0.000417	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.86e-06	0.000415	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.59e-06	0.000386	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.57e-06	0.000384	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	3.37e-06	0.000362	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.3e-06	0.000354	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.15e-06	0.000338	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.13e-06	0.000336	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.66e-06	0.000286	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.65e-06	0.000284	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	2.49e-06	0.000268	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	2.44e-06	0.000262	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	2.11e-06	0.000227	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.11e-06	0.000227	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	1.88e-06	0.000203	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.85e-06	0.000199	CbGpPWpGaD
Methadone—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	1.84e-06	0.000198	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	1.73e-06	0.000186	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	1.72e-06	0.000185	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.56e-06	0.000168	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	1.47e-06	0.000158	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.13e-06	0.000122	CbGpPWpGaD
